期刊文献+

肿瘤标记物联合检测对肿瘤高危人群筛查的临床意义 被引量:7

Clinical significicance of tumor markers combined detection in screening for tumor high-risk groups
原文传递
导出
摘要 目的 研究应用肿瘤标记物联合检测对恶性肿瘤高危人群筛查的临床价值.方法 选择血清肿瘤标记物组合对3 766例恶性肿瘤高危人员进行检测,对肿瘤标记(CA125、CEA、Cyfra21-1、CA19-9、AFP、NSE、CA72-4、SCC、CA153)升高人员进一步行颈胸部CT、腹盆部CT或内窥镜检查,女性进行妇科检查,未明确诊断者进行长期随访(大于6个月).结果 经过随访,共发现肿瘤患者69例,其中发现肿瘤标志物升高6个月内诊断为恶性肿瘤20例(62.5%),6个月至1年诊断5例(15.6%),1年至2年诊断4例(12.5%),2年至3年诊断2例(9.4%).COX分析显示肿瘤标志物升高的程度(RR=2.308,95% CI:2.517 ~2.475,P<0.001)、肿瘤标志物逐渐升高(RR=7.727,95% CI:3.008 ~ 19.836,P<0.05)和有相关临床症状(RR=7.879,95% CI:2.357 ~ 26.384,P<0.05)是筛查肿瘤标志物升高人员患肿瘤的危险因素.结论 血清肿瘤标记物联合检测对肿瘤筛查人群应答率高,危险因素调查是肿瘤筛查的有效手段. Objective To investigate the clinical value of combined detection of tumor markers in screening malignant tumor high-risk population.Methods 3 766 people with malignant tumor high-risk were tested with corresponding tumor markers CA125,CEA,Cyfra21-1,CA19-9,AFP,NSE,CA72 4,SCC,CA153 were rised.These people were inspected with cervico thoracicor,abdominal,and pelvic CT or endoscopy.Moreover,these women were followed up for more than 6 months.Results After follow-up,there were 69 cancer patients were found.Among them,20 cases (62.5 %) were diagnosed in 6 months with rised tumor markers,Five cases(15.9%) were diagosed as cancer in 6 months to 1 year.Four cases (12.5%) were diagosed in 1 to 2 years,and two cases (9.4%) were diagosed in 2 to 3 years.COX analysis showed that the degree of the elevated tumor markers (RR =2.308,95% CI:2.517 ~ 2.475,P 〈 0.001).The gradually increased tumor markers (RR =7.727,95% CI:3.008-19.836,P 〈 0.05),and relevant symptoms (RR =7.879,95% CI:2.357-26.384,P 〈 0.05) were the cancer risk factors.Conclusion Combined detection of serum tumor markers is an efficient methed in tumor screening.
出处 《国际免疫学杂志》 CAS 2016年第1期29-33,共5页 International Journal of Immunology
关键词 恶性肿瘤 早期诊断 肿瘤标记物 联合检测 Cancer Early detetion Tumor markers Combined detection
  • 相关文献

参考文献15

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J].CA Cancer J Clin,2005,55(2):74-108. DOI: 10.3322/ canjclin. 55.2.74.
  • 2Chen W,Zheng R,Zhang S,et al. Report of cancer incidence and mortality in China, 2010 [ J ]. Ann Transl Med, 2014,61 ( 10 ) : 2305-5839. DOI : 10. 3978/j. issn. 2014.04.05.
  • 3Haglund C, Kuusela P,Roberts P,et al. Tumour marker CA125 in patients with digestive tract malignancies[ J]. Scand J Clin Lab In- vest , 1991,51 ( 3 ) :265-270.
  • 4Ychou M, Dull'our J, Kramar A, et al. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in pa- tients with gastric cancer [ J ]. Dis Markers, 2000,16 ( 3-4 ) : 105- 110. DOI:10. 1155/2000/595492.
  • 5Li Y, Yang Y, Lu M, et al. Predictive value of serum CEA, CA19-9 and CA72-4 in early diagnosis of recurrence after radical resection of gastric cancer [ J ]. Hepatogastroenterology, 2011,58 ( 112 ) : 2166-2170. DOI : 10. 5754/hge11753.
  • 6Bornschein J, Selgrad M, Wex T, et al. Serological assessment of gastric mucosal atrophy in gastric cancer[ J]. BMC Gastroenterol, 2012,12:10. DOI:10. 1186/1471-230X-12-10.
  • 7Zur B, Hotdenrieder S, Walgenbach-Brtinagel G, et al. Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA betweenImmulite 2000 XPI and Dimension Vista 1500[ J]. Clin Lab,2012,58(1-2) :97-105.
  • 8Yang AP, Liu J, Lei HY, et al. CA72-4 combined with CEA, CA125 and CA19-9 improves the sensitivity for the early diagno- sisof gastric cancer [ J ]. Clin Chim Acta, 2014,437: 183-186. DOI: 10. 1016/j. cca. 2014.07. 034.
  • 9Howard BV,Van Hem L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease : the wonlen' 8 health initiative ran- domized controlled dietary modification trial [ J ]. AMA, 2006,295 ( 6 ) :655-666. DOI : 10.1001/jama. 295.6. 655.
  • 10Valnio H, Kaaks R, Bianehini F. Weight control and physical ac- tivity in cancer prevention: international evaluation of the evi- dence. [ J] Eur J Cancer Prev ,2002, l 1 ( Suppl 2 ) : s94-100.

同被引文献74

引证文献7

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部